OncoMatch/Clinical Trials/NCT03830320
Positron Emission Tomography (PET) Imaging of Thrombosis
Is NCT03830320 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including [64Cu]FBP8 and PET/MR for atrial fibrillation.
Treatment: [64Cu]FBP8 · PET/MR — The purpose of the study is to evaluate a new radiotracer called 64Cu-FBP8 for PET-MR imaging of thrombosis. The tracer has the potential of detecting thrombosis anywhere in the body, for instance in the left atrial appendage of patients with atrial fibrillation, and thereby may provide a non-invasive alternative to the current standard-of-care methods.
Check if I qualifyExtracted eligibility criteria
Prior therapy
Cannot have received: thrombolytics
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Massachusetts General Hospital · Boston, Massachusetts
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify